An integrated model of cellular states, tissue plasticity and genetics provides comprehensive insights for brain cancer immunotherapy
Image credit: Neftel et al. 2019
After PD-1 blockade, the T cells that expand don’t seem to be pre-existing tumor-infiltrating T lymphocytes but instead T cells with novel reactivities that weren’t previously present in the tumour
Image credit: Yost et al. 2019
Monitoring local vs. peripheral changes in cellular immunomes during cancer immunotherapy
Interesting study from Frontiers in Immunology & Duke University getting their biomarker immune analysis ready to go for an oncolytic virus trial for recurrent glioblastoma.
T-Scan: a genome-wide, high-throughput method for the systematic discovery of T cell epitopes
Image credit: Kula et al. 2019
The compartmental distribution of PD-L1 might dictate whether we should block it, knock it down or inhibit it during cancer immunotherapy
http://bit.ly/2ONuTZM
Image credit: Wu et al. 2019
Physically crosslinked injectable hydrogels for the long-term delivery of oncolytic viruses for cancer therapy
Image credit: Le et al. 2019
Fascinating paper describes how blocking tumour IFNg signalling can actually stimulate exhausted T cells to produce more IFNg & reject tumours with favorable antigenicity profiles
Image: Benci et al. 2019
Targeting cancer stem cells and their supportive niche using oncolytic virus immunotherapy
Image credit: Crupi et al. 2019
Cool new technology: empty-loadable tetramers that convert into antigen-specific tetramers by a single-step peptide addition & can identify neoantigen -specific T cells for cancer immunotherapy
http://bit.ly/2VmAkji
Image: Saini et al. 2019
Interesting review on rationally combining immunotherapy with synergistic radiotherapy to mobilise anti-cancer immunity
http://bit.ly/30UNpBI
Image credit: Herrera et al. 2019
compoundchem